Neoadjuvant capecitabine considered a new standard of care in rectal cancer

Single-agent neoadjuvant capecitabine combined with radiation therapy demonstrated similar outcomes as previously established standards of care for patients with stage II or stage III rectal cancer, according to findings from the four-arm phase III NSABP R-04 trial presented at a press conference prior to the 2014 Gastrointestinal Cancers Symposium held January 16-18.